참고문헌
- Acharya S, Chaudhuri S, Chatterjee S, et al (2010). Immunological profile of arsenic toxicity: a hint towards arsenic-induced carcinogenesis. Asian Pac J Cancer Prev, 11, 479-90.
- Acharya S, Chatterjee S, Kumar P, et al (2010). Induction of G1 arrest in glioma cells by T11TS is associated with upregulation of Cip1/Kip1 and concurrent downregulation of cyclin D (1 and 3). Anti-Cancer Drugs, 21, 53-64. https://doi.org/10.1097/CAD.0b013e32833276e8
- Antonsson B, Montessuit S, Lauper S, Eskes R, Martinou JC (2000). Bax oligomerization is required for channel forming activity in liposomes and to trigger cytochrome c release from mitochondria. Biochem J, 345, 271-8. https://doi.org/10.1042/0264-6021:3450271
- Bhattacharjee M, Acharya S, Ghosh A, et al (2008). Bax and Bid act in synergy to bring about T11TS mediated glioma apoptosis via the release of mitochondrial cytochrome c and subsequent caspase activation. Int Immunol, 20, 1489-505. https://doi.org/10.1093/intimm/dxn109
- Borner C. The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions (2003). Mol Immunol, 39, 615-47. https://doi.org/10.1016/S0161-5890(02)00252-3
- Chaudhuri S and Ghosh A (2006). Glioma Therapy: A novel insight in the Immunothrapeutic regime with T11TS/SLFA- 3. CNS Agents Medicinal Chem, 6, 245-70.
- Debatin KM, Krammer PH (2004). Death receptors in chemotherapy and cancer. Oncogene, 23, 2950-66. https://doi.org/10.1038/sj.onc.1207558
- Dranoff G (2004). Cytokines in cancer pathogenesis and Cancer therapy. Nature Rev Canc, 4, 411-22.
- Finucane DM, Bossy-Wetzel E, Waterhouse NJ, Cotter TG, Green DG (1999). Bax-induced Caspase Activation and Apoptosis via Cytochrome c Release from Mitochondria. Inhibitable by Bcl-xL. J Biol Chem, 274, 2225-33. https://doi.org/10.1074/jbc.274.4.2225
- Flora SJS, Bhadauria S, Kannan GM, Singh N (2007). Arsenic induced oxidative stress and the role of antioxidant supplementation during chelation: A review. J Environ Biol, 28, 333-47.
- Ghosh A, Bhattacharya M, Sarkar P, Acharya S, Chaudhuri S (2010). T11 target structure exerts effector function by activating immune cells in CNS against glioma where cytokine modulation provide favorable microenvironment. Ind J Exp Biol, 48, 879-88.
- Nayak AS, Lage CR Kim CH (2007). Effects of Low Concentrations of Arsenic on the Innate Immune System of the Zebrafish (Danio Rerio). Toxicol Sci, 98, 118-24. https://doi.org/10.1093/toxsci/kfm072
- Kaalia K, Flora SJS (2005). Strategies for Safe and Effective Treatment for Chronic Arsenic and Lead Poisoning. J Occup Health, 47, 1-21. https://doi.org/10.1539/joh.47.1
- Hilbert DM, Kopf M, Mock BA, Kohler G and Rudikoff S (1995). Interleukin 6 is essential for in vivo development of B lineage neoplasms. J Exp Med, 182, 243-8. https://doi.org/10.1084/jem.182.1.243
- Hunig T, Teifenthaler G, Mitnacht R, et al (1987). The "erythrocyte receptor" of T lymphocytes and T11 target structure (T11TS): Complementary cell interaction molecules involved in T cell activation. Behring Inst Mitt, 81, 31-40.
- Kannan GM, Flora SJS (2004). Chronic arsenic poisoning in the rat: treatment with combined administration of succimers and an antioxidant. Ecotoxicol Environ Safety, 58, 37-43. https://doi.org/10.1016/S0147-6513(03)00096-4
- Modi M, Mittal M, Flora SJS (2007). Combined administration of selenium and meso-2, 3-dimercaptosuccinic acid on arsenic mobilization and tissue oxidative stress in chronic arsenic-exposed male rats. Ind J Pharmacol, 39, 107-14. https://doi.org/10.4103/0253-7613.32530
- Liotta LA, Kohn EC (2001). The microenvironment of the tumour-host interface. Nature, 411, 375-9. https://doi.org/10.1038/35077241
- Mukherjee J, Dutta S, Sarkar S et al (2002). Preclinical changes in immunoreactivity and cellular architechture during the progressive development of intracranial neoplasms and an immunotherapeutic schedule with a novel biological response modifier, the T11TS/ S-LFA-3. Asian Pac J Cancer Prev, 3, 325-37.
- Paul WE (1989). Pleiotropy and redundancy: T cell-derived lymphokines in the immune response. Cell, 57, 521-4. https://doi.org/10.1016/0092-8674(89)90121-9
- Penn I (1994). Depressed immunity and the development of cancer. Cancer Detect Prev, 18, 241-52.
- Sabel MS, Arora A, Su G, et al (2007). Synergistic effect of intratumoral IL-12 and TNF-alpha microspheres: systemic anti-tumor immunity is mediated by both CD8+CTL and NK cells. Surgery, 142, 749-60. https://doi.org/10.1016/j.surg.2007.05.008
- Saini KS, Walker NI (1998). Biochemical and molecular mechanisms regulating apoptosis. Mol Cell Biochem, 178, 9-25. https://doi.org/10.1023/A:1006891430596
- Sarkar S, Ghosh A, Mukherjee J, Chaudhuri S and Chaudhuri S (2004). CD2-SLFA3/T11TS interaction facilitates immune activation and glioma regression by apoptosis. Canc Biol Ther, 3, 1121-8. https://doi.org/10.4161/cbt.3.11.1214
- Schmitz I., Meyer C, Schulze-Osthoff K (2006). CD95 ligand mediates T-cell receptor-induced apoptosis of a CD4+ CD8+ double positive thymic lymphoma. Oncogene, 25, 7587-96. https://doi.org/10.1038/sj.onc.1209741
피인용 문헌
- T11TS repress gliomagenic apoptosis of bone marrow hematopoietic stem cells vol.233, pp.1, 2018, https://doi.org/10.1002/jcp.25874